WallStSmart

Boston Scientific Corp (BSX)vsTivic Health Systems Inc (TIVC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 4164630% more annual revenue ($20.07B vs $482,000). BSX leads profitability with a 14.4% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

TIVC

Avoid

31

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for TIVC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

TIVC2 strengths · Avg: 9.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

TIVC4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.58M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-1.8%2/10

ROE of -1.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : TIVC

The strongest argument for TIVC centers on Price/Book, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : TIVC

The primary concerns for TIVC are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

TIVC carries more volatility with a beta of 2.01 — expect wider price swings.

TIVC is growing revenue faster at 15.9% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BSX scores higher overall (63/100 vs 31/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Tivic Health Systems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tivic Health Systems Inc (TIVC) is a pioneering medical technology firm focused on developing non-invasive bioelectronic therapies aimed at addressing chronic conditions, particularly allergic rhinitis. Leveraging its proprietary platform and extensive clinical expertise, Tivic Health is committed to delivering innovative solutions that not only meet critical patient needs but also optimize healthcare delivery. Positioned at the vanguard of the burgeoning bioelectronic medicine landscape, the company is set to seize emerging market opportunities, significantly improving patient outcomes and establishing new benchmarks in chronic condition management.

Want to dig deeper into these stocks?